Please login to the form below

Not currently logged in
Email:
Password:

Lilly launches innovation platform

Eli Lilly & Company has launched a drug discovery platform that aims to help boost the pharmaceutical company's R&D partnerships through a unique website

Eli Lilly & Company has launched a drug discovery platform focusing on developing treatments in areas of unmet medical need.

The platform is supported by the website openinnovation.Lilly.com through which scientists can submit molecules for Lilly to test to evaluate for further development. Data reports are then provided for them.

In the case of cancer, endocrine, cardiovascular and neuroscience screenings, Lilly said it would retain first rights to negotiate an agreement with the submitter in return for providing the data.

The platform itself consists of three components, the first of which screens submitted molecules for their potential to interact with known disease targets.

The second component then screens the molecules again in order to identify potential new medicines acting by novel mechanisms or pathways.

The final component screens molecules specifically for their potential as therapies for MDR-TB - a form of tuberculosis (TB) that is resistant to some TB medicines.

Dr Jan Lundberg, executive vice president, science and technology, and president, Lilly Research Laboratories, explained that partnership programmes were an increasing priority for Lilly in developing new products.

He said: "We recognise that there are many untapped sources of ideas and molecules outside of Lilly that would otherwise go unnoticed without initiatives like this one that advance science."

27th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics